Is Celcuity Inc (CELC) a risky stock?
As of July 21, 2026, Clavix grades Celcuity Inc (CELC) C+ for risk, a composite score of 68 out of 100 on an A+ to F scale, which puts CELC in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind CELC's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how CELC scores on each, as of July 21, 2026.
What's moving CELC's risk right now
Company-specific signals Clavix flags behind CELC's current grade, drawn from recent news and filings as of July 21, 2026.
Earnings are roughly in line with expectations, providing little catalyst in either direction.
This approval transforms Celcuity from a clinical-stage biotech into a commercial-stage company, potentially unlocking significant revenue in a large breast cancer market and vali…
What a C+ grade means
On the Clavix A+ to F scale, CELC's composite of 68 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell CELC or any security. Grades are risk indicators, not predictions of return. Data may be delayed.